Please login to the form below
respiratory syncytial virus
This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
AstraZeneca/Sanofi’s monoclonal antibody has been recommended by a US Food and Drug Administration’s (FDA) panel of experts for the prevention of respiratory syncytial virus (RSV) lower respiratory tract ... RSV is a common contagious virus
Latest news
-
GSK’s RSV vaccine approved by European Commission for older adults
GSK’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) for the prevention of RSV-caused lower respiratory tract disease (LRTD) in adults aged 60 years ... RSV is a common contagious virus characterised by
-
Pfizer’s RSV vaccine approved by FDA for older adults
Pfizer's respiratory syncytial virus (RSV) vaccine has been approved by the US Food and Drug Administration (FDA) for the prevention of RSV-caused lower respiratory tract disease (LRTD) in adults ... RSV is a common contagious virus characterised by
-
Pfizer’s maternal RSV vaccine candidate backed by FDA advisory committee
Pfizer’s respiratory syncytial virus (RSV) maternal vaccine candidate has been recommended for approval by a US Food and Drug Administration (FDA) panel of experts. ... Although most people recover within a week or two, the virus can potentially cause
-
GSK’s RSV vaccine approved by FDA for older adults
GSK’s respiratory syncytial virus (RSV) vaccine has been approved in the US for the prevention of RSV-caused lower respiratory tract disease (LRTD) in adults aged 60 years and older. ... RSV is a common contagious virus characterised by several mild,
-
GSK’s RSV vaccine candidate recommended by CHMP for older adults
GSK’s respiratory syncytial virus (RSV) vaccine candidate has been recommended by the European Medicines Agency’s human medicines committee for the prevention of RSV-caused lower respiratory tract disease (LRTD) ... There are currently no vaccines
More from news
Approximately 19 fully matching, plus 55 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
Up to that point, the drug was being developed to treat respiratory viral infections in patients with COPD who are at risk of experiencing exacerbations, which can be deadly and typically ... challenge study, in this case respiratory syncytial virus (RSV)
-
COVID-19: the race to find a vaccine
In the absence of a knockout antiviral, researchers are trying to mitigate harmful effects of the virus. ... Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.
-
Getting multichannel marketing right
has encouraged people to knit hats and blankets for babies to alert people to respiratory syncytial virus.
-
Deal Watch March 2017
In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.
-
Pharma deals during September 2014
Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Dutch biotech Mucosis promotes Thomas Johnston to CEO
During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
